Table 1.
Demographic and clinicopathological characteristics of ICC patients.
| All patients | Training group (n = 58) | Validation group (n = 24) | X2/T/Z | P | |
|---|---|---|---|---|---|
| Age, years, average ± SD | 63.49 ± 10.02 | 63.26 ± 9.50 | 64.04 ± 11.38 | -0.320 | 0.750 |
| Gender, n (%) | 0.394 | 0.530 | |||
| Male | 40 (48.78%) | 27 (46.55%) | 13 (54.17%) | ||
| Female | 42 (51.22%) | 31 (53.45%) | 11 (45.83%) | ||
| PMI, n (%) | 0.236 | 0.627 | |||
| High | 41 (50.00%) | 30 (51.72%) | 11 (45.83%) | ||
| Low | 41 (50.00%) | 28 (48.28%) | 13 (54.17%) | ||
| TNM stage, n (%) | 1.829 | 0.401 | |||
| III | 22 (26.83%) | 18 (31.03%) | 4 (16.67%) | ||
| II | 17 (20.73%) | 11 (18.97%) | 6 (25.00%) | ||
| I | 43 (52.44%) | 29 (50.00%) | 14 (58.33%) | ||
| Tumor differentiation, n (%) | 2.061 | 0.151 | |||
| High/middle | 54 (65.85%) | 41 (70.69%) | 13 (54.17%) | ||
| Low | 28 (34.15%) | 17 (29.31%) | 11 (45.83%) | ||
| Location, n (%) | 3.397 | 0.065 | |||
| Left | 47 (57.32%) | 37 (63.79%) | 10 (41.67%) | ||
| Right | 35 (42.68%) | 21 (36.21%) | 14 (58.33%) | ||
| Tumor size, cm, n (%) | 0.394 | 0.530 | |||
| >5 | 40 (48.78%) | 27 (46.55%) | 13 (54.17%) | ||
| ≤5 | 42 (51.22%) | 31 (53.45%) | 11 (45.83%) | ||
| Tumor number, n (%) | 0.000 | 1.000 | |||
| Multiple | 12 (14.63%) | 8 (13.79%) | 4 (16.67%) | ||
| Single | 70 (85.37%) | 50 (86.21%) | 20 (83.33%) | ||
| Hepatitis B, n (%) | 0.482 | 0.487 | |||
| Positive | 25 (30.49%) | 19 (32.76%) | 6 (25.00%) | ||
| Negative | 57 (69.51%) | 39 (67.24%) | 18 (75.00%) | ||
| Lymph node invasion, n (%) | 0.483 | 0.487 | |||
| Yes | 12 (14.63%) | 10 (17.24%) | 2 (8.33%) | ||
| No | 70 (85.37%) | 48 (82.76%) | 22 (91.67%) | ||
| Vascular invasion, n (%) | 4.823 | 0.028 | |||
| Yes | 13 (15.85%) | 13 (22.41%) | 0 (0.00%) | ||
| No | 69 (84.15%) | 45 (77.59%) | 24 (24.00%) | ||
| Perineural invasion, n (%) | 0.149 | 0.700 | |||
| Yes | 14 (17.07%) | 11 (18.97%) | 3 (12.50%) | ||
| No | 68 (82.93%) | 47 (81.03%) | 21 (87.50%) | ||
| Cancer embolus, n (%) | 4.196 | 0.041 | |||
| Yes | 19 (23.17%) | 17 (29.31%) | 2 (8.33%) | ||
| No | 63 (76.83%) | 41 (70.69%) | 22 (91.67%) | ||
| Capsule invasion, n (%) | 2.346 | 0.126 | |||
| Yes | 13 (15.85%) | 12 (20.69%) | 1 (4.17%) | ||
| No | 69 (84.15%) | 46 (79.31%) | 23 (95.83%) | ||
| BMI, kg/m2, average ± SD | 0.242 | 0.809 | |||
| 22.38 ± 3.33 | 22.43 ± 3.48 | 22.24 ± 3.00 | |||
| Hepatolithiasis, n (%) | 0.020 | 0.887 | |||
| Yes | 40 (48.78%) | 28 (48.28%) | 12 (50.00%) | ||
| No | 42 (51.22%) | 30 (51.72%) | 12 (50.00%) | ||
| AFP, ng/ml, Median (IQR) | -0.025 | 0.980 | |||
| 2.89 (2.54) | 2.77 (1.83) | 2.90 (2.55) | |||
| CEA, μg/L, Median (IQR) | -1.035 | 0.301 | |||
| 3.00 (3.33) | 2.85 (3.63) | 3.15 (3.03) | |||
| CA199, U/ml, Median (IQR) | -0.357 | 0.721 | |||
| 50.20 (542.53) | 57.35 (434.98) | 39.70 (1911.30) | |||
| Diabetes, n (%) | 1.238 | 0.266 | |||
| Yes | 16 (19.51%) | 9 (15.52%) | 7 (29.17%) | ||
| No | 66 (80.49%) | 49 (84.48%) | 17 (70.83%) | ||
| Smoking, n (%) | 0.129 | 0.719 | |||
| Yes | 21 (25.61%) | 16 (27.59%) | 5 (20.83%) | ||
| No | 61 (74.39%) | 42 (72.41%) | 19 (79.17%) | ||
| Alcohol consumption, n (%) | 0.099 | 0.754 | |||
| Yes | 17 (20.73%) | 11 (18.97%) | 6 (25.00%) | ||
| No | 65 (79.27%) | 47 (81.03%) | 18 (75.00%) | ||
| Liver cirrhosis, n (%) | 1.031 | 0.310 | |||
| Yes | 18 (21.95%) | 11 (18.97%) | 7 (29.17%) | ||
| No | 64 (78.05%) | 47 (81.03%) | 17 (70.83%) | ||
| Albumin, g/L, average ± SD | -0.690 | 0.492 | |||
| 38.87 ± 7.07 | 38.52 ± 9.67 | 39.71 ± 8.50 | |||
| PLR, n (%) | 0.943 | 0.332 | |||
| >147.93 | 41 (50%) | 31 (53.45%) | 10 (41.67%) | ||
| ≤147.93 | 41 (50%) | 27 (46.55%) | 14 (58.33%) | ||
| NLR, n (%) | 0.068 | 0.795 | |||
| >2.53 | 53 (64.63%) | 38 (65.52%) | 15 (62.50%) | ||
| ≤2.53 | 29 (35.37%) | 20 (34.48%) | 9 (37.50%) | ||
| LMR, n (%) | 0.183 | 0.669 | |||
| >2.92 | 38 (46.34%) | 26 (44.83%) | 12 (50%) | ||
| ≤2.92 | 44 (53.66%) | 32 (55.17%) | 12 (50%) | ||
| ASA, n (%) | 0.000 | 1.000 | |||
| 3-4 | 3 (3.66%) | 2 (3.45%) | 1 (4.17%) | ||
| 1-2 | 79 (96.34%) | 56 (96.55%) | 23 (95.83%) |